27
Apr
2008
Posted in I - Series B, Q - 1Q08, R - ROCKY MOUNTAIN, X - AMD, X - Asthma, X - Inflammation
Taligen Therapeutics (Aurora, CO) a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease closed a $65M Series B financing. Participants include Alta Partners, Clarus Ventures, Sanderling Ventures, Tango and High Country Venture.
27
Apr
2008
27
Apr
2008
27
Apr
2008
27
Apr
2008
27
Apr
2008
27
Apr
2008
27
Apr
2008
27
Apr
2008
27
Apr
2008